Kristopher Brown is a partner in the firm’s Life Sciences group. Mr. Brown negotiates and structures private equity and venture capital financing transactions. He also advises on corporate and transactional matters for numerous financial and corporate strategic investors as well as emerging growth companies in the life sciences, healthcare, financial and technology sectors.

Mr. Brown has experience in the full range of complex commercial transactions, including mergers and acquisitions, divestitures, public offerings, licensing transactions, the formation of investment partnerships, and the creation of strategic and collaborative alliances and joint ventures. Practicing for more than 20 years, Mr. Brown has advised on more than 250 transactions in the life sciences sector alone. In addition, he counsels investors, management executives, and boards of directors on governance and regulation issues and securities law matters.

Mr. Brown is listed as a “Life Sciences Star” and a “U.S. Transactional Rising Star” by LMG Life Sciences and has been listed as a recommended lawyer for life sciences and capital markets: equity and global offerings by The Legal 500, where he was cited as being “highly skilled and committed” and noted for the “strength of his client relationships.”

Prior to joining Goodwin in 2018, Mr. Brown was a partner at Dechert LLP.









Mr. Brown has advised on award-winning life sciences deals, including:

Capital Markets

  • Olink Holding AB (publ) in its $265 million IPO on Nasdaq in the U.S.
  • Calliditas Therapeutics in its upsized $90 million IPO on Nasdaq in the U.S.
  • Bicycle Therapeutics in its $60 million IPO on Nasdaq in the U.S.
  • Advaxis, Inc. in multiple follow-on financings on Nasdaq
  • Zealand Pharma in its $75 million IPO on Nasdaq in the U.S.*
  • Forward Pharma in its $221 million IPO on Nasdaq in the U.S., which won M&A Advisor’s “Healthcare/Life Sciences Sector Deal of the Year” award*


  • Johnson & Johnson in the sale of its BabyCenter business to Everyday Health Group
  • Johnson & Johnson in the sale of one of its drug product lines to Baxter
  • Johnson & Johnson in the transfer of collaboration rights and assets to Pharma Mar
  • Remedy Pharmaceuticals’ sale to Biogen, in a transaction which received a “Commended” ranking at the Financial Times North American Innovative Lawyers 2017 Awards*
  • Lazada Group on the $1 billion sale of a controlling stake in the company to Alibaba, which was named “M&A Deal of the Year: Southeast Asia” at The Asian Lawyer’s 2017 Asia Legal Awards*
  • AM-Pharma’s sale of a minority interest in the company to Pfizer Inc. and related option payment, which was a finalist for the 2015 Scrip Awards*

Licensing + Collaborations

  • Johnson & Johnson in its strategic alliance with Apple to deploy the Apple Watch to detect atrial fibrillation
  • Johnson & Johnson in its partnership with Verily (f/k/a Google Life Sciences) to innovate advanced surgical robots, which won LMG’s “2015 Collaboration Deal of the Year”*

Royalty Monetizations

  • Barings in the purchase of certain rights from George Washington University related to the license by GWU of its vasoconstrictor drug to La Jolla Pharmaceutical Company
  • Onxeo in the $7.5 million royalty and milestone monetization from SWK Holdings of Onxeo’s oncology drug to treat refractory peripheral T cell lymphoma
  • Zealand Pharma in the $205 million royalty and milestone monetization from Royalty Pharma of Zealand’s GLP-1 diabetes franchise
  • Zealand Pharma’s monetization of certain royalty rights under its license agreement with Sanofi-Aventis, which was a finalist for the 2015 Scrip Awards*

Venture Capital

  • Johnson and Johnson UK Treasury Company Limited as lead investor of the $1.3 billion Series B financing of Grail, Inc., which was named LMG Life Sciences 2017 “Impact Deal of the Year”*

*Denotes experience prior to joining Goodwin.


  • 强生公司将其孕婴保健公司BabyCenter业务出售给Everyday Health Group
  • Bicycle Therapeutics在美国纳斯达克上市
  • Advaxis, Inc.在纳斯达克多次后续融资
  • 强生公司向百特出售其一条药品生产线
  • 强生公司将合作权利和资产转让给Pharma Mar
  • 强生公司与苹果公司结成战略联盟,通过苹果手表来提供房颤检测
  • Zealand Pharma与Royalty Pharma of Zealand就糖尿病特许经营权达成了2.05亿美元货币化交易
  • Remedy Pharmaceuticals出售给渤健公司,这项交易获得了“2017年金融时报北美创新律师奖” *
  • Johnson and Johnson UK Treasury Company Limited作为主要投资者参与Grail, Inc., 13亿美元B轮融资,这项交易获得了《LMG生命科学》“2017年最具度影响力交易” *
  • Forward Pharma A/S在美国纳斯达克上市,这项交易获得了M&A顾问公司的“年度医疗保健/生命科学行业交易奖”*
  • 强生公司与Verily(原名为谷歌生命科学公司)联合设计先进的手术机器人,这项交易获得了《LMG生命科学》 “2015年度最佳合作交易”*
  • AM-Pharma’s将其少数股权及相关的期权出售给辉瑞,这项交易入围行业瞩目的2015 SCRIP年度大奖*
  • 根据与赛诺菲-安万特的许可协议,Zealand Pharma’s将其特许权货币化,这项交易也入围2015 SCRIP年度大奖*

此外,宗律师曾为电子商务公司Lazada Group向阿里巴巴出售10亿美元公司控股权项目提供了建议,该交易获得2017年亚洲律师协会颁发的亚洲法律大奖“年度最佳并购交易:东南亚”。*

* 加入高赢之前的经验

Professional Activities

Mr. Brown is a member of the American Bar Association, the New York State Bar Association, and the Association of the Bar of the City of New York.



Professional Experience

Mr. Brown is a member of Brown University’s Advisory Council on Entrepreneurship, and is also a member of the National Advisory Council for, and served until 2018 as the pro bono outside general counsel to In addition, Mr. Brown serves on the investor board of Venture for America, the advisory board of Lyfebulb, as a Blueprint Health mentor, and as a member of the Nordic Mentor Network for Entrepreneurship, or NOME.


宗律师是布朗大学创业咨询委员会的成员,也是国家咨询委员会的成员,并在2018年之前担任DonorsChoose.org的公益外部总顾问。此外,宗律师还是美国风险投资公司的投资者委员会、Lyfebulb的顾问委员会、Blueprint Health 导师以及北欧企业家导师网络(NOME)的成员。


In November 2021, Mr. Brown was nominated by the Nordic Mentor Network for Entrepreneurship (NOME) for its inaugural NOME award which recognizes mentors who have been particularly active and made a difference for NOME over the past year.

In The News









JD, 1992
Boston University School of Law

(magna cum laude)

AB, 1989
Brown University

(magna cum laude, Phi Beta Kappa)


法学博士, 1992
Boston University School of Law

(magna cum laude)

AB, 1989
Brown University

(magna cum laude, Phi Beta Kappa)



New York


U.S. District Court for the Southern District of New York





Profile Image
Get In Touch
Our clients rely on us for world-class advisory services, counsel on complex transactional work and high-stakes litigation. Specializing in matters involving the financial, life sciences, private equity, real estate, and technology industries, we use a collaborative, cross-disciplinary approach to resolve our clients’ most challenging issues. To find out more, please contact us.


Nos équipes interviennent aux côtés de nos clients, industriels, fonds d’investissement, startups, institutions financières et dirigeants, dans le cadre de transactions et de contentieux complexes, et apportent des conseils de tout premier plan dans les secteurs financiers, des Sciences de la Vie, du Private Equity, de l’immobilier et des technologies. Nous traitons les dossiers juridiques de manière intègre, ingénieuse, souple et audacieuse pour répondre efficacement aux enjeux propres à chacun de nos clients, quels que soient la taille de l’opération et le secteur d’activité. Pour en savoir plus, contactez-nous.

Unsere Kunden verlassen sich auf unsere erstklassige Beratung, vor allem im Hinblick auf komplexe Transaktionen und High-Stakes-Prozesse. Spezialisiert auf Angelegenheiten der Finanz-, Life-Sciences-, Private-Equity-, Immobilien-und Technologie-Branchen, verwenden wir einen kooperativen und interdisziplinären Ansatz, um Fragen unserer Kunden auch in extremen Spezialsituationen einer Lösung zuzuführen. Sie wollen mehr erfahren? Kontaktieren Sie uns gerne.

Search Other Lawyers
Recherche par Pratique